Contrast Induced AKI Clinical Trial
Official title:
Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection
This trial was performed to examine the efficacy of oral L-arginine for preventing CI-AKI in chronic kidney disease (CKD) patients.
Contrast-induced acute kidney injury (CI-AKI) is a common complication in hospitalized
patients. Nitric oxide-signal transduction plays an important role in prevention of CI-AKI.
L-Arginine is an amino acid involved in ammonia detoxification, and is well known as a
precursor to nitric oxide, a key component of endothelial-derived relaxing factor.
This is a prospective randomized, double blind, placebo controlled trial among CKD stage 3-4
patients undergoing computer tomography. Eligible patients were randomly assigned to two
groups: (1) arginine 3 g/day or 6 capsules per day, and (2) placebo 6 capsules per day for 3
days before contrast media injection. Serum cystatin C, serum creatinine and estimated GFR
was measured at baseline and 48 hours after procedure.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention